General Information
We are a cellular analysis company that is discovering new cancer sub-types and commercializing diagnostic tests designed to significantly improve the clinical outcomes of cancer patients treated with targeted therapies. Our proprietary CELx diagnostic platform is the only commercially ready technology we are aware of that uses a patient’s living tumor cells to identify the specific abnormal cellular process driving a patient’s cancer and the targeted therapy that best treats it.
Employees: 15
Founded: 2012
Contact Information
Address 16305 36th Avenue N., Suite 450, Minneapolis, MN 55446, US
Phone Number (763) 392-0123
Web Address http://www.celcuity.com
View Prospectus: Celcuity
Financial Information
Market Cap $92.4mil
Revenues $0 mil (last 12 months)
Net Income $-4.5 mil (last 12 months)
IPO Profile
Symbol CELC
Exchange NASDAQ
Shares (millions): 2.4
Price range $9.50 - $9.50
Est. $ Volume $22.8 mil
Manager / Joint Managers Craig-Hallum Capital Group
CO-Managers -
Expected To Trade: 9/20/2017
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change